Literature DB >> 23729691

Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.

Helmut U Klein1, Ilan Goldenberg, Arthur J Moss.   

Abstract

The benefit of implantable cardioverter-defibrillator (ICD) therapy depends upon appropriate evaluation of a persisting risk of sudden death and estimation of the patient's overall survival. Assessment of a stable and unchangeable arrhythmogenic substrate is often difficult. Structural abnormality and ventricular dysfunction, the two major risk parameters, may recover, and heart failure symptoms can improve so that ICD therapy may not be indicated. Risk stratification can take time while the patient continues to be at high risk of arrhythmic death, and patients may need temporary bridging by a defibrillator in cases of interrupted ICD therapy. The wearable cardioverter-defibrillator (WCD) combines a long-term electrocardiogram (ECG)-monitoring system with an external automatic defibrillator. The LIfeVest® (ZOLL, Pittsburgh, PA, USA) is composed of a garment, containing two defibrillation patch electrodes on the back, and an elastic belt with a front-defibrillation patch electrode and four non-adhesive ECG electrodes, connected to a monitoring and defibrillation unit. The WCD is a safe and effective tool to terminate ventricular tachycardia/ventricular fibrillation events, unless a conscious patient withholds shock delivery. It may be used in patients in the early phase after acute myocardial infarction with poor left ventricular function, after acute coronary revascularization procedures (percutaneous coronary intervention or coronary artery bypass grafting) and reduced left ventricular ejection fraction (≤35%), in patients with acute heart failure in non-ischaemic cardiomyopathy of uncertain aetiology and prognosis. The WCD may be helpful in subjects with syncope of assumed tachyarrhythmia origin or in patients with inherited arrhythmia syndromes. The WCD may replace ICD implantation in patients waiting for heart transplantation or who need a ventricular-assist device. This review describes the technical details and characteristics of the WCD, discusses its various potential applications, and reports the currently available experience with the wearable defibrillator.

Entities:  

Keywords:  ICD therapy; Risk stratification; Sudden cardiac death; Wearable cardioverter-defibrillator

Mesh:

Year:  2013        PMID: 23729691     DOI: 10.1093/eurheartj/eht167

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  32 in total

1.  [Mismanagement in the arrhythmia recognition algorithm of the LifeVest® with consecutive fatal outcome].

Authors:  M Sorleto; H Wuttig; E Aydilek; M Wiemer
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2016-02-01

2.  [Pacemaker dependant and/or repetitive ICD therapies. How to solve the dilemma of lead extraction?].

Authors:  Viviane Möller; Frank Hölschermann; Thomas Schau; Christian Butter
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-08-17

Review 3.  Tools for risk stratification of sudden cardiac death: a review of the literature in different patient populations.

Authors:  Loheetha Ragupathi; Behzad B Pavri
Journal:  Indian Heart J       Date:  2014-01-11

4.  Usefulness of the wearable cardioverter defibrillator in patients in the early post-myocardial infarction phase with high risk of sudden cardiac death: A single-center European experience.

Authors:  Yusuke Kondo; Markus Linhart; René P Andrié; Joerg O Schwab
Journal:  J Arrhythm       Date:  2015-05-14

5.  Ventricular Arrhythmia after Acute Myocardial Infarction: 'The Perfect Storm'.

Authors:  Justine Bhar-Amato; William Davies; Sharad Agarwal
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-08

6.  The Day I Died.

Authors:  Julie M Stausmire; Mitchell G Greenbaum; Marie Morelli-Greenbaum
Journal:  Ann Fam Med       Date:  2018-01       Impact factor: 5.166

7.  The wearable cardioverter-defibrillator in a real-world clinical setting: experience in 102 consecutive patients.

Authors:  Julia W Erath; Mate Vamos; Abdul Sami Sirat; Stefan H Hohnloser
Journal:  Clin Res Cardiol       Date:  2016-11-25       Impact factor: 5.460

8.  Use of the wearable cardioverter-defibrillator (WCD) and WCD-based remote rhythm monitoring in a real-life patient cohort.

Authors:  Maura M Zylla; Henrike A K Hillmann; Tanja Proctor; Meinhard Kieser; Eberhard Scholz; Edgar Zitron; Hugo A Katus; Dierk Thomas
Journal:  Heart Vessels       Date:  2018-05-02       Impact factor: 2.037

9.  Wearable Cardioverter-Defibrillator after Myocardial Infarction.

Authors:  Jeffrey E Olgin; Mark J Pletcher; Eric Vittinghoff; Jerzy Wranicz; Rajesh Malik; Daniel P Morin; Steven Zweibel; Alfred E Buxton; Claude S Elayi; Eugene H Chung; Eric Rashba; Martin Borggrefe; Trisha F Hue; Carol Maguire; Feng Lin; Joel A Simon; Stephen Hulley; Byron K Lee
Journal:  N Engl J Med       Date:  2018-09-27       Impact factor: 91.245

10.  [A 65-year-old man with wearable cardioverter/defibrillator early after acute myocardial infarction].

Authors:  F W Horlbeck; G Nickenig; J O Schwab
Journal:  Internist (Berl)       Date:  2015-09       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.